Final answer:
Pharmacists must notify the appropriate regulatory body as required by state law after being sued for malpractice; the specifics can vary by jurisdiction, and these procedures differ from the FDA's adverse event reporting process.
Step-by-step explanation:
If a pharmacist is sued for malpractice, the board of pharmacy or relevant regulatory body must be notified as required by the specific state's law or regulations. Notification timeframes can vary by jurisdiction, but it is generally expected that the notification occurs promptly after the lawsuit is filed. While the details provided from LibreTexts mention the procedure for notifying the FDA about adverse drug experiences after NDA approval, it should be noted that this process is different from the malpractice reporting requirement for pharmacists. Malpractice issues are typically handled by state pharmacy boards rather than the FDA, which focuses on drug safety and efficacy at a federal level. However, understanding the post-approval reporting obligations to the FDA emphasizes the ongoing responsibility of healthcare providers, including pharmacists, to monitor and report safety concerns.